Neoadjuvant use of Imiquimod Before Surgery in Extramammary Paget’s Disease

ABSTRACT – Extramammary Paget's disease (EMPD) is a distinct form of a rare malignant skin neoplasm, primarily seen in post-menopausal Caucasian women. Surgery is the most common treatment. However, concerning vulvar EMPD, radical surgery can be mutilating and leads to loss of femininity. Recent therapeutic development has included medical and medical-surgical approaches, allowing better preservation of genital anatomy with subsequent reduced morbidity. Accordingly, off-label use of imiquimod has been reported as a monotherapy or adjuvant therapy in EMPD.

We report the case of a woman with extensive EMPD in the anogenital area, submitted to surgical resection complemented with plastic reconstruction and preceded by imiquimod medical treatment. Neoadjuvant imiquimod induced a significant cytoreduction of the tumor area, minimizing surgical radicality and maintaining local function and morphology.

KEYWORDS – Imiquimod; Neoadjuvant Therapy; Paget Disease, Extramammary/therapy; Vulvar.
INTRODUCTION
Extramammary Paget's disease (EMPD) is a distinct form of a rare malignant skin neoplasm, an intraepithelial neoplasia of glandular cells, first reported by Crocker in 1889 in the scrotum and penis. Vulvar Paget's disease was first reported in 1901 by Dubreuilh. EMPD is primarily seen in postmenopausal Caucasian women and the most common site of involvement is the vulva, where it represents less than 1% of the vulvar malignancies and is rarely invasive (<10%). It typically appears as erythematous, scaly or moist, eczematous lesions with irregular borders, accompanied by pruritus. Vulvar Paget's disease often spreads in an occult fashion extending beyond the clinically apparent edges of the lesion. These patients are at risk for a second synchronous or metachronous neoplasm, namely, colorectal adenocarcinoma, adenocarcinoma of the cervix, carcinoma of the transitional epithelium from the renal pelvis to the urethra, breast and vulvar carcinoma. Staging should include examination of the entire cutaneous integument, evaluation of draining lymph nodes and exclusion of genitourinary and colorectal malignant tumors. Recent therapeutic modalities have emerged. Surgery, by default, is the most common treatment, but it is challenging to excise the disease adequately, and recurrence is common, leading to repeated surgical procedures and mutilation. The use of neoadjuvant therapies prior to surgery has been performed in many neoplasias, allowing tumor cytoreduction, making subsequent surgical excision easier. We report a case of a woman with extensive EMPD in the anogenital area treated with neoadjuvant imiquimod before excisional and reconstructive surgery.

CASE REPORT
A 67-year-old woman was referred for evaluation of a pruritic, anogenital lesion, resistant to topical antifungals and corticosteroids with months of evolution. Her medical history included an infiltrating ductal carcinoma of the breast 17 years before, submitted to left mastectomy, radiotherapy and hormone therapy. Physical examination revealed a 16 x 7 cm large, erythematous, scaly plaque with irregular but well demarcated borders, centered by small erosions, localized in the genital and perianal areas (Fig. 1). No inguinal adenopathies or extragenital cutaneous lesions were found. Histopathology showed cells with large abundant pale-staining cytoplasm and large nuclei, with prominent nucleoli infiltrating the epidermis without dermal invasion (Fig. 2a-b). It was immunopositive for CK7, CEA, GCDFP-15, CAM5.2 and EMA, and negative for S-100 and CK20. Thorough gynecological evaluation, thoraco-abdomino-pelvic computed tomography, pelvic magnetic resonance, proctoscopy and cystoscopy excluded synchronous malignancies. Laboratory evaluations were unremarkable except for syphilis serology, which revealed late latent syphilis promptly treated with benzathine penicillin G 2,4 million units weekly, 3 doses.

The diagnosis of primary intraepithelial EMPD was confirmed. To achieve tumor reduction before surgery patient was treated with imiquimod 5% cream, 3 times per week, for 12 weeks with partial response. To maximize the clinical response, it was increased to daily application, but was stopped 5 weeks later due to systemic symptoms (anorexia, headache...
and dizziness). At this point substantial tumor reduction was seen (Fig. 3) and patient underwent partial bilateral vulvectomy with V-Y fasciocutaneous flap reconstruction (Fig. 4). Histopathology revealed Paget’s disease involvement of the surgical margins at the right labia majora of the vulva. A relapse was seen after one year of follow-up (Fig. 5). The patient restarted imiquimod application 3 times per week, while awaiting surgical reintervention.

**DISCUSSION**

EMPD lesions are generally confined to the epidermis, but it can invade the dermis and metastasize to regional lymph nodes or distant organs.9 Mohs micrographic surgery or wide local excision are the traditional therapeutic options.10,11 Recently, a safe resection margin of 2 cm has been recommended.10,11

EMPD lesions commonly develop in apocrine-rich areas such as the vulva, penis, scrotum, perianal, and axilla, consequently, tissue loss and functional impairment after surgery are associated with significant morbidities.10,12 Concerning vulvar EMPD, it is very important to avoid the long-term complications of radical surgery, such as pain and scarring, a feeling of mutilation, loss of femininity and also, adverse impact on sexual function.4 Actually, surgeons face a huge challenge: balance between potentially extensive radical surgery (which allows free surgical margins reducing theoretically the relapse) versus conservative surgery (which preserves genital anatomy and function).10 Furthermore, indistinct borders, subclinical extensions and multifocal nature associated with EMPD result in high recurrence rates despite adequate surgical resection margins.10,13 In 2013, Edey et al published a Cochrane review evaluating the different treatment modalities for vulvar Paget’s disease. They found that most studies stated that margin status had no impact on recurrence. Similarly, a recent review of 89 cases of vulvar Paget’s disease by Onaiwu et al found no association between margin status and recurrence rates. Given the potential negative sequelae and the high rate of recurrence, a more conservative approach may be of benefit when there is no evidence of an underlying adenocarcinoma.14

Generally, EMPD appears as carcinoma in situ and has a favorable prognosis. However, in about 20% of cases EMPD progresses to an invasive tumor, invasive EMPD (iEMPD), which can metastasize mainly through the lymphatic channels and become fatal.15 A TNM evaluation has been recently proposed by Ohara et al.15 Other treatment options include topical imiquimod, topical 5-fluorouracil, topical bleomycin sulfate, intralesional interferon-α, radiation therapy, cryotherapy, chemotherapy, laser ablation and photodynamic therapy.8,10 Imiquimod is a biological response modifier, which stimulates both innate and acquired immune function resulting in potent antiviral, antitumor and immunoregulatory properties.1,12 After Zampogna et al publication of 2 cases of primary limited cutaneous perineal and genital EMPD treated with imiquimod 5%, 16 off-label use has been successfully reported as a monotherapy or adjuvant therapy in EMPD.1,8,9,10,12,14 A recent systematic review reported a response rate to imiquimod ranging from 50% to 80% with a recurrence rate about 20%.1 Imiquimod seems to be efficient
also in cases of EMPD recurrence and was reported as an interesting neoadjuvant treatment before surgery by Toledo et al,8 to reduce tumor size before surgery. However, there are also reports of failure after imiquimod treatment in EMPD.17 The optimal frequency and length of treatment time remains to be defined.1 The intensity of imiquimod’s effect is dose-dependent and so the probability of local and systemic side effects is increased with daily application, as experienced by our patient.12

Our patient presented with an extensive EMPD affecting a great part of the anogenital region. The neoadjuvant treatment with imiquimod 5% cream, induced a significant chemical cytoreduction of the tumoral area (histologically confirmed after the excision once the periphery of the lesion was free of neoplasia except at one location) allowing a later surgical excision of an otherwise inoperable/highly mutilating neoplasm. In addition to the clinical reduction of the tumor area after treatment with imiquimod, histopathology revealed a complete response in the margins except for one area.

CONCLUSION

Immune modulators, such as imiquimod, can be a good alternative as a neoadjuvant treatment previous to surgery in selected cases of extensive EMPD. Promising results have been published recently in the literature validating the need for well-designed clinical trials.

REFERENCES